The aim of this study is firstly to assess the tolerance of the sunscreen RV4857A-CD2110 after 28 days and 57 days of at least a twice daily on the study areas, secondly to assess anti-imperfection efficacy after 28 days and 57 days of use and its efficacy against recurrence of acne lesions post-sun exposure.
Age range
12 Years – 40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Assessment of the dermatological physical signs
Timeframe: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Assessment of the dermatological functional signs
Timeframe: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Assessment of the ophthalmological physical signs
Timeframe: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Assessment of the ophthalmological functional signs
Timeframe: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Assessment of the Tear film Break Up Time (BUT)
Timeframe: Change from Baseline to 30 minutes after product application, to 29 and 57 days later
Assessment of global tolerance assessment (dermatogical assesment), a 5-point scale
Timeframe: Change from Baseline to 29 and 57 days later
Assessment of global tolerance assessment (ophthalmological assessment), a 5-point scale
Timeframe: Change from Baseline to 29 days later